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Abstract
Hepatitis B virus (HBV) replicates its 3 kb DNA genome through capsid-internal reverse
transcription, initiated by assembly of 120 core protein (HBc) dimers around a complex of
viral pregenomic (pg) RNA and polymerase. Following synthesis of relaxed circular (RC)
DNA capsids can be enveloped and secreted as stable virions. Upon infection of a new cell,
however, the capsid disintegrates to release the RC-DNA into the nucleus for conversion
into covalently closed circular (ccc) DNA. HBc´s interactions with nucleic acids are mediated
by an arginine-rich C terminal domain (CTD) with intrinsically strong non-specific RNA bind-
ing activity. Adaptation to the changing demands for nucleic acid binding during the viral life
cycle is thought to involve dynamic phosphorylation / dephosphorylation events. However,
neither the relevant enzymes nor their target sites in HBc are firmly established. Here we
developed a bacterial coexpression system enabling access to definably phosphorylated
HBc. Combining Phos-tag gel electrophoresis, mass spectrometry and mutagenesis we
identified seven of the eight hydroxy amino acids in the CTD as target sites for serine-argi-
nine rich protein kinase 1 (SRPK1); fewer sites were phosphorylated by PKA and PKC.
Phosphorylation of all seven sites reduced nonspecific RNA encapsidation as drastically as
deletion of the entire CTD and altered CTD surface accessibility, without major structure
changes in the capsid shell. The bulk of capsids from human hepatoma cells was similarly
highly, yet non-identically, phosphorylated as by SRPK1. While not proving SRPK1 as the
infection-relevant HBc kinase the data suggest a mechanism whereby high-level HBc phos-
phorylation principally suppresses RNA binding whereas one or few strategic dephosphory-
lation events enable selective packaging of the pgRNA/polymerase complex. The tools
developed in this study should greatly facilitate the further deciphering of the role of HBc
phosphorylation in HBV infection and its evaluation as a potential new therapeutic target.
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Author summary
The liver-pathogenic hepatitis B virus (HBV) is a small enveloped DNA virus that repli-
cates through reverse transcription of a pregenomic (pg)RNA. This requires specific
encapsidation of pgRNA and viral polymerase into a shell of 240 core protein (HBc) sub-
units. Capsid-internal formation of relaxed circular (RC) DNA enables the particle to
leave the cell as stable virion; yet, when infecting a new cell it must release the RC-DNA
for conversion into another, plasmid-like DNA that templates new viral RNAs. This up
and down in nucleic acid interactions is presumably regulated by transient phosphoryla-
tion of HBc, mainly in its arginine-rich C terminal domain (CTD) which displays strong
non-sequence-specific RNA binding. However, neither the phosphorylation sites nor the
relevant enzymes are well defined. We developed a recombinant system to produce
kinase-specific phospho-HBc species, and adapted a feasible gel assay for their separation.
By mutagenesis and mass spectrometry we identified seven target sites for a major candi-
date kinase, SRPK1, in the CTD. As full SRPK1 phosphorylation thwarted non-specific
RNA binding the comparably high phosphorylation of HBc in human cells suggests how
specific pgRNA encapsidation might be achieved. Our new tool set will facilitate disentan-
gling the role of HBc phosphorylation in HBV infection and exploiting it as potential ther-
apeutic target.
Introduction
Chronic infection with hepatitis B virus (HBV) puts more than 250 million people at a greatly
increased risk to develop terminal liver disease [1]. HBV, the prototypic hepadnavirus, is a
small enveloped virus that replicates its 3 kb DNA genome through capsid-internal reverse
transcription of a pregenomic (pg) RNA (reviewed in [2, 3]). The virion envelope consists of a
lipid bilayer into which the small (S), middle (M; PreS2/S) and large (L; PreS1/PreS2/S) surface
proteins are embedded [4–6]. Binding of L to the HBV receptor sodium taurocholate cotrans-
porting polypeptide (NTCP) is essential for infection (reviewed in [7]); in addition, L contrib-
utes a "matrix domain" that interacts with the capsid for virion morphogenesis (reviewed in
[8]).
The icosahedral HBV capsid (core particle) is composed of 120 dimers (triangulation num-
ber T = 4) of a single core protein (HBc) species of 183–185 amino acids (aa) in length; a
minor capsid class (T = 3) comprises 90 HBc dimers. The HBc monomer encompasses an N
terminal assembly domain [9], linked through residues 141–149 [10] to an arginine-rich C ter-
minal domain (CTD; Fig 1A). The CTD is crucial for specific co-encapsidation of a complex of
pgRNA and viral polymerase (P protein) during replication but it can also mediate non-
sequence-specific packaging of RNA (Fig 1B), e.g. when HBc is expressed in E. coli [9, 11–13].
Structural analyses of such capsid-like particles (CLPs), mostly from CTD-less variants like
HBc149 [9], revealed five α-helices [14–16]. Helices α3 and α4 form an antiparallel hairpin;
for dimerization, two such hairpins associate into four-helix bundles which protrude as spikes
from the capsid surface (Fig 1B). Helix α5 plus the downstream sequence to position 140 har-
bor the major inter-dimer contacts.
Little is known about the structure of the CTD; in current CLP structures the visible
sequence commonly ends within the linker [10, 14–19]. Regarding CTD disposition most data
support a luminal localization [20–23]. However, a permanent internal disposition as well as a
static nucleic binding capacity are incompatible with the full set of HBc functions in the viral
life-cycle (Fig 1C). Beyond pgRNA/P protein encapsidation these include CTD-mediated
HBV core protein phosphorylation sites
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reverse transcription [24] into single-stranded (ss) minus-DNA and then partly double-
stranded (ds) relaxed circular (RC) DNA [24–26]; capsid envelopment for secretion of virions
[8]; and, upon infection of a new cell, transport of the viral genome to the nuclear pore so as to
release the RC-DNA into the nucleoplasm [27, 28] for conversion into covalently closed circu-
lar (ccc) DNA [29, 30]. Nuclear transport requires binding of CTD-encoded nuclear localiza-
tion signals (NLSs; [31]) to cytosolic transport receptors [32–35] such that at least one CTD
per capsid must become exposed [18, 27, 32, 36, 37].
Hence the capsid must safely stow ss and also ds nucleic acid with twice as many negative
charges and then orderly let go of it.
A likely mechanism underlying these CTD dynamics is transient phosphorylation, early-on
hinted at by a capsid-associated protein kinase activity [38, 39]. However, neither this kinase
nor other potentially HBc-relevant kinases have unambiguously been identified. Proposed
candidates include Ca2+ and/or lipid-activated protein kinase C (PKC; [36, 40]); cyclic AMP
dependent protein kinase A (PKA; [41, 42]); serine/arginine-rich protein kinase 1 and 2
(SRPK1, SRPK2; [43]); cyclin-dependent kinase 2 (CDK2; [44]); and polo-like kinase 1 (PLK1;
[45]). Major analytical challenges are the presence in human cells of>500 protein kinases plus
>200 phosphatases [46]; the repetitve nature of the HBc CTD sequence (Fig 1A); the limited
specificity of pharmacological kinase inhibitors; and especially the lack of assays that feasibly
distinguish non-phosphorylated and differently phosphorylated HBc species.
As a surrogate, various studies assessed the impact of serine and/or threonine (S/T) replace-
ments in HBc by alanine (A) to prevent phosphorylation, and by aspartic acid (D) or glutamic
acid (E) to mimic phosphorylation [47–50]. Collectively these data suggest that phosphoryla-
tion is necessary early and some dephosphorylation late during replication. However, genetic
mimics cannot model the dynamics of phosphorylation. Phospho-HBc-specific antibodies [51,
52] are valuable but they interrogate only few of the many options for phosphorylation site
Fig 1. Structural and functional aspects of HBc. (A) Domain organization. Numbers refer to aa positions. The immunodominant c/e1 epitope, in the 3D structure at
the tips of the capsid spikes, and mutation F97L are indicated. Residues 141–149 (blue) link the assembly domain to the CTD which encompasses 16 basic R residues
(red) and one acidic E residue (green). Phosphorylation of the S/T residues would reduce positive charge. (B) Non-sequence-specific RNA packaging by HBc in E.
coli. HBc forms dimers that spontaneously assemble into CLPs. With HBc183, the basic CTDs mediate encapsidation of ~3–4 kb non-sequence-specific RNA. In HBV
infection this would compete with specific encapsidation of viral pgRNA. (C) Basic functions of HBc in the HBV life-cycle. HBc is required to interact with different
forms of viral genomic nucleic acid (NA) while avoiding interactions with irrelevant NAs. Progeny virus particles leaving a cell must be environmentally stable, yet upon
infection of a new cell they must orderly release the viral NA for nuclear cccDNA formation. This implies temporal changes in NA binding capacity and capsid
structure, including CTD disposition. (D) Options for capsid structure modulation. Regulated structure modulation is manifest by the selective, L protein dependent
envelopment of dsDNA (or no NA) containing capsids (symbolized by the altered shape and color of the HBc dimer in the center) but not of capsids harboring RNA or
ssDNA. Sensing the type of internal NA must involve the CTDs, and likely their phosphorylation status. The negatively charged phosphoryl groups could directly affect
CTD—assembly domain interactions (i) and/or CTD disposition (ii), or act indirectly through altered NA binding (iii). Mutations like F97L evade this dependency,
possibly by a priori promoting an envelopment-proficient structure.
https://doi.org/10.1371/journal.ppat.1007488.g001
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occupancy. Correlation with specific replication states is further convoluted by the variety of
capsid forms, including nonenveloped capsids [53] and the recently found enveloped genome-
less capsids ("empty virions"; [52]) which seem to by far outnumber infectious virions
(reviewed in [54]).
The most direct evidence for the dynamics in core protein phosphorylation comes from
duck HBV (DHBV). Intracellular DHBV core protein (DHBc) showed up to four distinct
phosphorylation-dependent bands in normal SDS-PAGE [55] whereas virion-derived DHBc
displayed a single, non-phosphorylated band, as confirmed by mass spectrometry (MS) [56].
The presence in virions of mostly mature viral ds DNA [57], similarly observed for HBV [58],
supported the "maturation signal" hypothesis [57] whereby capsid-internal genome matura-
tion, perhaps sensed by the CTDs and/or their phosphorylation status, exposes interaction
sites for L protein on the capsid surface (Fig 1D). The finding that also empty though not ss
nucleic acid containing capsids can be enveloped prompted a revised model whereby RNA or
ssDNA actively inhibit envelopment [52, 59]. A cryoEM comparison between recombinant
RNA containing capsids and serum virus-derived, supposedly dsDNA bearing capsids had
indeed revealed subtle differences [17]. However, at the time empty virions in serum [52, 60]
were not known; hence potential envelopment-relevant structural differences and their corre-
lation with HBc phosphorylation remain open (Fig 1C, i-iii).
Some natural HBc mutations such as F97L [61–63] promote secretion of immature, ssDNA
containing virions. Such capsid proteins might by default adopt an envelopment-proficient
conformation (Fig 1D). Yet, while affecting in vitro assembly [64] no differences in stability or
morphology between wild-type and F97L HBc particles were detectable [63, 65]. However, a
potential role of phosphorylation could not be assessed at the time.
In sum a large body of data supports correlations between HBc phosphorylation, genome
maturation and capsid structure, including CTD disposition and envelopment-competence;
however, fundamental information for disentangling these interdependencies is lacking.
In order to generate such information we here established the efficient recombinant pro-
duction of distinct phospho-HBc species and showed the feasibility of Phos-tag SDS-PAGE
[66] for their differentiation. Using MS and mutagenesis we identified seven hydroxy amino
acid residues in the CTD as target sites for SRPK1 [34, 43] while PKA and PKC modified
fewer, yet to be mapped sites. Full occupancy of the SRPK1 sites massively reduced HBc183
CLP RNA content while abrogation of one phospho-site restored substantial RNA binding.
Full phosphorylation also caused differences in CTD accessibility to trypsin, regardless of the
F97L mutation. Importantly, in human hepatoma cells the bulk of HBc appeared as highly
phosphorylated as SRPK1-coexpressed HBc. These data pave the way for a comprehensive
characterization of the substrate properties of hepadnaviral core proteins for individual kinases
and phosphatases. Virologically they suggest a mechanism whereby high-level HBc phosphor-
ylation principally suppresses RNA binding whereas one or few dephosphorylation events
could enable specific packaging of the pgRNA/P protein complex.
Results
A robust bacterial coexpression system for phosphorylated HBV core
protein
Eukaryote-like S/T protein kinases are rare in eubacteria [67] and apparently absent from E.
coli laboratory strains. Hence co-expression of HBc with a mammalian kinase should allow the
background-free evaluation of its action on HBc. In a first step we created T7 promoter-based
vectors carrying an E. coli codon usage adapted HBc gene (HBc183opt) to boost expression of
full-length HBc183 (Fig 1A). CLP yields were indeed around three-fold higher (S1 Fig)
HBV core protein phosphorylation sites
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compared to the older non-optimized HBc gene [68] in the same pET28a2 vector [69, 70], and
they increased further using pRSF-Duet derived vectors (see below).
For the coexpression approach the recombinant kinase must be enzymatically active and
target sites in HBc must not be sequestered by CLP formation. We thus chose human SRPK1
as the first candidate HBc kinase. Beyond its very high affinity for the HBc CTD [34, 43, 71]
we had already shown HBc phosphorylating activity of the full-length enzyme in bacteria [11];
here we used an N terminally His6-tagged variant, NHisSRPK1ΔNS1, in which an internal
deletion boosts soluble expression in bacteria [72].
To minimize experimental variations seen when HBc and kinase were expressed from two
separate plasmids [11] we devised a single-vector dual expression system; it features a Tet
repressor / anhydrotetracycline (AHT) inducible Tet promoter cassette plus an isopropyl β-D-
1-thiogalactopyranoside (IPTG) regulatable T7 promoter cassette (S2 Fig). Functionality was
shown by inducer-specific expression of eGFP from one and mCherry from the other cassette
(S2 Fig). HBc183opt in the T7 cassette was expressed at up to five-fold higher levels than from
the pET28a2 vector (S3 Fig). Of note, expression from the Tet cassette was affected by the spe-
cific ORF sequence. For instance, the basal level of NHisSRPK1ΔNS1 expression without AHT
was still about one third as high as with inducer (S3A Fig); hence in subsequent SRPK1 coex-
pression experiments AHT was omitted.
Either way, in line with its high affinity for HBc [34, 43] most of the SRPK1 cosedimented
with the CLPs, both from wild-type and F97L HBc (S3 Fig); separation was achieved by immo-
bilized metal ion chromatography (IMAC) under semi-denaturing conditions (S4 Fig). Alto-
gether, the system provided easy access to milligram amounts of CLPs per 100 ml of induced
bacterial culture.
Strongly reduced RNA content of HBc183 CLPs by SRPK1 coexpression
Low level co-expression in E. coli of full-length SRPK1 with HBc183 had generated a mixture
of HBc species containing from one to several phosphoryl groups [11]; this prompted the fol-
low-up use of a triple S>E variant, HBc183-EEE (S155E_S162E_S170E) as a homogeneous
genetic mimic of such partially phosphorylated HBc183 [34, 35]. HBc183-EEE CLPs contained
~25% less RNA than wild-type HBc183 CLPs [73]. To evaluate the impact on CLP RNA con-
tent of the much higher NHisSRPK1ΔNS1 expression in our new system we separated the
CLPs by NAGE, then stained packaged RNA by ethidium bromide (EB) and the protein shell
by Coomassie Brillant Blue (CB) [9, 74]; other stains, e.g. Sybr Green 2 (SG2) for RNA and
Sypro Ruby (SR) for protein [75], could be used instead (see below). The intensity of RNA vs.
protein stain per band is proportional to the CLP´s RNA content.
Fig 2A shows such an analysis for HBc183_F97L expressed in the absence (-SRPK) vs. pres-
ence of SRPK1. Despite much weaker EB staining the +SRPK1 samples showed even stronger
CB staining; in either case abundant CLPs were visible in negative staining EM; wild-type
HBc183 CLPs gave comparable results. To appreciate the extent of reduction in RNA content
caused by NHisSRPK1ΔNS1 coexpression we used a reference set of CLPs from C terminally
truncated HBc proteins, starting with the CTD-less variant HBc140. SG2 and SR allowed semi-
quantitative assessment of the relative fluorescence intensities of each band (Fig 2B) using a
laser scanner (Typhoon FL7000, GE Healthcare). The ratio of RNA: protein fluorescence for
non-phosphorylated HBc183 CLPs was set to 100%, to which the ratios for the other CLPs
were normalized. Accordingly, SRPK1-coexpressed HBc183 CLPs contained nominally 27%
as much RNA as the HBc183 reference CLPs, very similar to CTD-less HBc140 CLPs. For the
other variants, the ratios increased with increasing CTD length, in accord with the electrostatic
"charge balance" hypothesis [13, 26, 76].
HBV core protein phosphorylation sites
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An estimate of absolute CLP RNA content as molar ratio of nucleotides (N) per core pro-
tein (P) subunit (N/P) was obtained from UV-VIS spectra by deconvoluting the superimposed
RNA and protein absorbances [73]; spectra were recorded using gradient-enriched CLPs in-
cubated with 1/100 the amount of (w/w) of RNase A and subsequently dialyzed to remove non-
packaged RNA. For HBc183 CLPs we obtained (N/P) values ± standard deviation (SD) of 16.4
±2.2 (n = 8); for a T = 4 CLP this corresponds to an RNA content equivalent to ~4,000 nt, similar
to other reports [12, 73]. Much in contrast, SRPK1-coexpressed HBc183 CLPs gave a ratio of only
2.3±0.5 (n = 8), not significantly different from CTD-less HBc140 (2.9±1.3; n = 4) and HBc149
CLPs (1.8±1.5; n = 4). Intermediate RNA contents were found for HBc161, 163, 166 and 173
CLPs, as shown in Fig 2C in comparison with the NAGE/SG2:SR procedure. While the apparent
overestimation of low RNA contents by the latter method could later be reduced by several
improvements (Materials and Methods), both data sets corroborated that SRPK1 coexpression
reduced RNA content as strongly as deletion of the entire CTD. This implied a phosphorylation
extent sufficient to shift assembly to an RNA-independent, protein-protein interaction driven
mechanism [37, 77], perhaps by neutralizing most of the positive CTD charges [13].
Phos-tag SDS-PAGE indicates high-level HBc183 phosphorylation by
SRPK1ΔNS1
The Phos-tag chelator coordinated with two Me2+ ions binds to phosphoryl groups, including
in proteins [78]. In SDS-PAGE gels containing copolymerized Phos-tag acrylamide and loaded
with Mn2+ or Zn2+ phospho-proteins migrate more slowly than their non-phosphorylated
forms [66]. Hence this technique appeared attractive to detect HBc phosphorylation. After
optimization we routinely used home-made gels containing 75 μM Phos-tag acrylamide
loaded with 150 μM Mn2+. As shown in Fig 3, in normal SDS-PAGE both HBc183 and
HBc183_F97L migrated to the same ~21 kDa position, regardless of SRPK1 coexpression. In
Fig 2. Coexpression with SRPK1 strongly reduces HBc CLP RNA content. (A) Visualization of RNA content in HBc183_F97L CLPs by NAGE and RNA
vs. protein staining. HBc183_F97L CLPs expressed in the absence (-) or presence (+) of NHisSRPK1ΔNS1 were enriched to sucrose gradient sedimentation.
The indicated fractions were separated by NAGE in the presence of ethidium bromide (EB); subsequently proteins were stained by Coomassie Blue (CB). Note
the high vs. low EB to CB signal ratios in the -SRPK1 vs. the +SRPK1 samples but their nearly identical mobility. Negative staining EM (EM) did not reveal
differences between the two HBc183_F97L samples, nor between the respective wild-type HBc183 samples (S3B Fig). (B) Impact of NHisSRPK1ΔNS1
coexpression vs. CTD truncations on RNA content. CLPs from the indicated truncated HBc variants were subjected to NAGE in EB-free gels, then stained with
Sybr Green 2 (SG2) for RNA; after documentation the gels were counterstained with Sypro Ruby (SR) for protein. Green and red signals were semiquantitatively
evaluated by laser scanning at the indicated conditions (grey-scale panels). The ratios of SG2 to SR fluorescence in each sample are given as percent of the
respective value for HBc183 CLPs expressed without kinase. (C) Similarly strong reduction in absolute CLP RNA content by NHisSRPK1ΔNS1 coexpression
as by CTD deletion. RNA contents of the indicated HBc CLPs (in nt per HBc protein monomer (N/P)) were calculated from UV/VIS spectra [73]. Black bars
show the mean N/P values ± SD (n�3). For comparison, the relative values derived from (B) are shown as grey bars; the scale was set such that the 100% value
(HBc183) matched the mean N/P value (~16) of the same sample. In either assay, the RNA content of HBc183 and HBc183_F97L CLPs coexpressed with SRPK1
was as low as that of HBc140 CLPs.
https://doi.org/10.1371/journal.ppat.1007488.g002
HBV core protein phosphorylation sites
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Phos-tag SDS-PAGE, however, exclusively the kinase-coexpressed proteins exerted a drasti-
cally reduced mobility.
Band ladders produced in in vitro SRPK1 phosphorylation and lambda phosphatase
dephosphorylation reactions with a non-assembling GFP-CTD fusion protein suggested phos-
phorylation at five or more positions. Analogous coexpression of HBc183 with the catalytic
domains of PKA (Genbank NP_032880.1) and PKC theta (Genbank NP_001269573.1), chosen
owing to their reportedly functional expression in E. coli [79, 80], caused a less pronounced
retardation (see below).
Mass spectrometry defines seven SRPK1 phosphorylation sites in HBc
The number of phosphoryl groups introduced into HBc183 by SRPK1 was analyzed by
matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) MS. The major
MH+ peaks in the relevant 21 kDa region of the spectra had mass/charge (m/z) values of
21,103 for mono-expressed HBc183 and 21,664 for SRPK1-coexpressed HBc183. These values
match most closely to the calculated masses of 21,116 Da for completely unmodified HBc183,
and to 21,676 Da for a seven-fold phosphorylated HBc183 (S5 Fig; each phosphoryl group con-
tributes ~80 Da). Notably, for SRPK1-coexpressed HBc140 and HBc149 the main peaks still
corresponded to the non-phosphorylated proteins; hence the assembly domain and the linker
sequence lack SRPK1 target sites.
For more accurate mass determination we devised a method (S1 protocol) to isolate just the
CTD peptide from a tobacco etch virus (TEV) protease cleavable NHisGFP-TEV-CTD fusion
protein (Fig 4A), expressed with or without kinase. Cleavage reduces the relevant masses to
~5,000 Da, with a synthetic N-acetylated CTD peptide serving as reference (Fig 4B). Methods
development included replacement of the C terminal Cys residue by Ala (C183A in full-length
HBc numbering). In brief, the NHisGFP-TEV-CTD protein was enriched by Ni2+ IMAC
Fig 3. Strong and selective retardation of SRPK1-coexpressed wild-type and F97L HBc183 in Phos-tag
SDS-PAGE. Samples from the indicated gradient-enriched CLPs expressed alone (-) or coexpressed with SRPK1 (+)
were separated by normal SDS-PAGE (left panel) or by Mn2+ Phos-tag SDS-PAGE (right panel). The weak bands at
the 45 kDa position marked by arrowheads (left panel) represent SRPK1 that had co-sedimented with the HBc CLPs.
https://doi.org/10.1371/journal.ppat.1007488.g003
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under semi-denaturing conditions, then incubated with His-tagged TEV protease [81] to
release the CTD peptide; all His-tagged components (uncleaved GFP fusion protein, the GFP-
containing cleavage product and TEV protease) were removed by another round of IMAC.
The clipped-off CTD peptide in the flow-through was concentrated and further enriched by
ultrafiltration. An SDS-PAGE analysis of the final products obtained upon coexpression with
SRPK1ΔNS1 or the PKA catalytic domain (PKAcd) or without kinase, alongside the synthetic
CTD peptide, is shown in Fig 4C.
Importantly, MS of the SRPK1 sample (Fig 4D) showed one major peak with excellent
agreement to a seven-fold but not six- or eight-fold phosphorylated CTD peptide. Hence there
are seven SRPK1 target sites in the HBc sequence 146–183. The m/z values for the synthetic
and the non-phosphorylated fusion protein-derived CTD peptide were <1 Da off the calcu-
lated masses (S6 Fig). The PKA-coexpressed sample showed two main peaks, matching four
and five phosphoryl groups, respectively; for full-length HBc183 as substrate the products
Fig 4. Accurate MS confirmation of seven SRPK1 phosphorylation sites in the HBc CTD. (A) Genetic structure of
the non-assembling CTD fusion constructs. The dual promoter vectors carried an ORF for non-His-tag kinase
(SRPK1ΔNS1, or the catalytic domain of PKA) plus an ORF for a His-tagged GFP protein to which the CTD of HBc
variant C183A was linked via a TEV protease recognition site; see text and S1 Protocol for details. (B) Calculated MH+
masses of the indicated CTD derivatives vs. observed m/z values. Note the excellent agreement for a seven-fold
phosphorylated CTD species in the +SRPK1 sample. (C) SDS-PAGE of the purified CTD peptides from the
indicated GFP fusion proteins. The sequence of the chemically synthesized N-acetylated sCTD peptide carrying the
genuine C183 residue is shown in (B). (D) MALDI-TOF spectrum of the +SRPK1 CTD sample from (C). Note the
predominance of the m/z peak corresponding to seven-fold phosphorylated CTD. Mass spectra for the other CTD
peptides are shown in S6 Fig.
https://doi.org/10.1371/journal.ppat.1007488.g004
HBV core protein phosphorylation sites
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from PKA and PKC coexpression carried only three phosphoryl groups (S7 Fig), possibly due
to assembly-mediated target site sequestration.
Mapping of the seven SRPK1 phosphorylation sites by mutagenesis plus MS
To identify the seven SRPK1 sites in HBc we individually mutated the seven S residues plus
one T residue in the CTD (S155, T160, S162, S168, S170, S172, S178 and S181) to A, coex-
pressed the mutant proteins with SRPK1 and monitored phosphorylation by MS (Fig 5A) and
by immunoblotting after Phos-tag SDS-PAGE.
For all mutants but one MS revealed a best match to the six-fold phosphorylated forms, i.e.
loss of one phosphorylation site. The exception was mutant S181A which still matched best to
a seven-fold phosphorylated species. Hence all hydroxy amino acids in the HBc CTD including
T160 yet except S181 are substrates for SRPK1. Double and triple S/T>A mutants confirmed
the data as the number of lost phosphorylation sites always corresponded to the number of S/T
replacements by A (or by G or R), except when S181 was mutated (S7 Fig).
In line with their at least six-fold phosphorylation all single S/T variants were similarly
strongly retarded in Phos-tag SDS-PAGE as SRPK1-coexpressed wild-type HBc183, as shown
Fig 5. Mapping the SRPK1 phosphorylation sites in the HBc CTD by mutation and MS. (A) Position of S/T>A
mutations, dominant m/z peak observed and calculated MH+ mass of best-fitting phospho-species. Note that
S181A is the only single-site variant with a best-fit m/z for seven-fold phosphorylation; all other single-site mutants
showed the best match to six phosphoryl groups. (B) Impact of number and position of phospho-sites on Phos-tag
SDS-PAGE mobility. Following Phos-tag SDS-PAGE HBc proteins were analyzed by immunoblotting using the HBc
assembly-domain specific mAb 1D8. All SRPK1-coexpressed proteins contained seven (HBc183, S181A) or six
phosphoryl groups (all others) but variants S170A (�) and especially T160A and S162A (��) were less retarded, even
though much more than three-fold PKAcd phosphorylated HB183. The impact of the mutations on recognition by the
phospho-CTD specific mAb T2212 is shown in S12 Fig. (C) Impact on CLP RNA content. CLPs from the indicated
HBc proteins were analyzed by NAGE and sequential SG2 vs. SR staining using an improved, background-reducing
protocol (Materials and Methods). SG2: SR ratios are indicated in percent of that in non-phosphorylated HBc183
CLPs. Bars show the mean of�3 determinations; error bars represent standard deviation (SD). Original NAGE
fluorograms plus data for additional variants are shown in S8 Fig. Note the exceptionally low SG2 to SR ratio for S181A
and the higher ratio for S170A vs. all other single S/T>A variants (red arrows). The minor impact of PKA and PKC
coexpression on RNA content (blue bars) correlated with the predominance of only three-fold phosphorylated species
(S7 Fig) and their less pronounced retardation in Phos-tag SDS-PAGE (Fig 5B and Fig 9C).
https://doi.org/10.1371/journal.ppat.1007488.g005
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by immunoblotting (Fig 5B) with the assembly domain-directed anti-HBc mAb 1D8 [82].
Notably, though, the correlation between the number of phosphorylation sites and mobility
was not strictly linear. The six-fold phosphorylated variants S155A, S176A, and S178A
migrated about as slowly as the seven-fold phosphorylated wild-type protein and variant
S181A. In contrast, the likewise six-fold phosphorylated variants T160A, S162A and S170
(marked with asterisks in Fig 5B) had distinctly higher mobilities. Hence beyond the number
of phosphoryl groups also their sequence context contributes to the interaction with the Phos-
tag. Knowledge of the S/T>A variants´ phosphorylation status also enabled a more detailed
characterization of the epitope requirements of mAb T2212 (see below).
We then evaluated the impact of the S/T>A mutations on CLP RNA content by the NAGE
based SG2/SR staining assay (Fig 5C, S8 Fig) but using a more elaborate protocol (Material
and Methods). Owing to the lower background signals the relative RNA contents of HBc140,
HBc149 and SRPK1-coexpressed HBc183 as well as HBc183_S181A CLPs were now estimated
to�10% of that in unmodified HBc183 CLPs (Fig 5C). The mostly three-fold phosphorylation
by PKA and PKC caused only minor reductions (significant only for PKC). Remarkably, pre-
venting phosphorylation at one of the seven SRPK1 sites was sufficient to increase RNA con-
tents to generally ~20–30% of non-phosphorylated HBc183 CLPs; additional phosphorylation
site mutations further increased RNA content (S8 Fig). Intriguingly, the single S170A muta-
tion restored RNA content to ~50% of unmodified wild-type HBc183 CLPs, and this difference
to the other single variants was significant (p<0.001; n = 6). Hence phosphorylation of S170
may be particularly effective in suppressing RNA binding by the HBc CTD.
Little impact of high phosphorylation status, low RNA content and F97L
mutation on CLP stability against SDS
HBc183 CLPs are sensitive against SDS [9, 65]; hence titration with SDS might reveal whether
high-level phosphorylation and/or the concomitant low RNA content affect CLP stability. To this
end we incubated HBc183 CLPs and HBc183_F97L CLPs expressed in the absence vs. presence of
SRPK1 with either 1x TAE electrophoresis buffer (Ø), or a native glycerol-based DNA loading
buffer (Ø�), or increasing amounts of a 6x DNA loading buffer (NEB Purple) containing 0.48%
SDS (0.08% at 1x concentration). RNA and protein were monitored by EB and CB staining;
expectedly, SRPK1-coexpressed CLPs showed only faint EB versus CB signals (Fig 6, right panels).
At 0.024% SDS the nonphosphorylated CLPs released some of the RNA (faster migrating
EB smear) although the major band remained at the original position. At 0.048% SDS, the fast
RNA smear increased, while the original CLP band disappeared in favor of a slower, less
intense band from which EB signals emanated upwards to the cathode; still higher SDS con-
centrations enhanced these effects. CB staining of the latter bands suggests they may represent
complexes of HBc183 proteins with exposed CTDs (forced to move towards the cathode) to
which some of the initially encapsidated RNA is bound. In accord with previous data [65] no
clear difference was detectable for wild-type vs. F97L CLPs. Interestingly the SRPK1-pho-
sphorylated low RNA CLPs also showed a sharp mobility transition between 0.024% and
0.048% SDS, although the new products migrated a bit slower than those from the nonpho-
sphorylated CLPs. In sum, SDS sensitivity of the HBc CLPs was neither affected by seven-fold
phosphorylation of the CTD, nor by RNA content or the F97L mutation.
Altered HBc CLP trypsin sensitivity by high-level phosphorylation and low
RNA content
The high arginine content makes the entire HBc CTD an excellent substrate for trypsin; how-
ever, protease accessibility is affected by the CLP structure [37, 65, 83]. In our hands, trypsin
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had converted part of the unmodified wild-type HBc183 into a major product with HBc149-
like mobility [83]. To reveal potential alterations of this pattern by phosphorylation, RNA con-
tent and/or the F97L mutation, we monitored the kinetics of trypsin action on non-phosphor-
ylated vs. phosphorylated CLPs from wild-type and F97L HBc183 protein.
First we addressed a potential inhibition of trypsin cleavage by CTD phosphorylation by
comparing the trypsin sensitivity of the non-assembling NHis-GFP-TEV-CTD fusion protein
(see Fig 4A) expressed in the absence vs. presence of SRPK1. Both proteins were completely
cleaved with similar kinetics (Fig 7A, left panel). Under the same conditions, HBc183 in non-
phosphorylated CLPs was only partially cleaved within 30 min (Fig 7A, right panel), with
about half the molecules remaining intact and the other half displaying HBc149-like mobility;
this pattern remained stable over 2 h.
Higher temporal resolution (Fig 7B) revealed the transitory formation of intermediate mobility
bands which had mostly disappeared at 30 min in favor of the stable HBc149-like product (labeled
"4"); thereafter the ratio between presumably intact HBc183 (labeled "1") and product "4" re-
mained constant for at least 4 h. NAGE did not reveal significant alterations in EB vs. CB staining
over time (Fig 7B, lower panels). Hence loss of half the CTDs affected neither RNA content nor
surface charge, indicating the overall CLP structure remained intact. Comparable results with
HBc183_F97L CLPs (Fig 7C) ruled out major effects of the F97L mutation.
Fig 6. Little impact on SDS sensitivity of CLPs by high phosphorylation, low RNA content and F97L mutation.
About 5 μg HBc protein from the indicated CLP preparations were directly loaded (Ø), or after 30 min incubation in
non-denaturing 6x DNA loading buffer (Ø�) or in SDS-containing DNA loading buffer (NEB Purple) at the indicated
final SDS concentrations, then analyzed by NAGE. A 1 kb DNA ladder (M) plus 1 μg of untreated HBc183 CLPs
served as markers. EB fluorescence signals (top) were recorded using a laser scanner (excitation 532 nm/O580 nm
filter). Proteins were subsequently stained by CB. In all samples the intact CLP bands became fuzzier at 0.024% SDS
compared to the untreated controls, and a distinct upward mobility shift occurred at 0.048% SDS. For the non-
phosphorylated CLPs (-SRPK1) this was accompanied by visible release of RNA.
https://doi.org/10.1371/journal.ppat.1007488.g006
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In contrast, SRPK1-coexpressed HBc183 CLPs (Fig 7D, top panel) presented two additional
discrete, stable products ("2" and "3") of which product 3 eventually reached similar levels as
the remaining full-length protein. By comparison with HBc marker proteins (Fig 7D, lower
panel) products 3 and 2 resulted from cleavage between positions 157–159 and 166–172,
respectively. HBc_F97L CLPs produced a very similar four-band pattern in SDS-PAGE (Fig
7E, top panel); in NAGE CLP mobility and RNA content again remained unaltered (Fig 7E,
bottom panels). While quantitation of the band 1 to 4 proportions could be disturbed by the
presence of not fully intact CLPs, formation of bands 2 and 3 exclusively from the phospho-
CLPs strongly implies distinct steric constraints for the band 2 and 3 processing sites com-
pared to unmodified CLPs. Scenarios compatible with the data (complete CTD extrusion vs.
looping out of CTD parts) are shown in S9 Fig.
Fig 7. Strong impact on CLP trypsin sensitivity by high level phosphorylation and low RNA content but not the
F97L mutation. (A) Full cleavage of accessible but not CLP-borne CTD regardless of phosphorylation. NHis-
GFP-CTD fusion protein expressed with or without SRPK1, and HBc183 CLPs were incubated as indicated with 1%
(w/v) trypsin; digestion was stopped by AEBSF and reactions were analyzed by SDS-PAGE and CB staining. Non-
phosphorylated and phosphorylated GFP-CTD fusion protein were completely cleaved with comparable kinetics. In
the CLPs less than half the HBc183 subunits were rapidly cleaved into a 15 kDa product; the 14 kDa lysozyme band (ly)
in some samples originates from the cell lysis procedure. (B) Non-phosphorylated HBc183 CLPs. Trypsin incubation
and inhibition were done as in (A). Reaction products were analyzed by SDS-PAGE and NAGE (lower panels) with EB
and CB staining. Note the overall unaltered NAGE signals despite cleavage of about half the subunits; intact versus
cleaved chains are labeled 1 and 4. (C) Non-phosphorylated HBc183_F97L CLPs. As for HBc183 CLPs, uncleaved
chains (1) plus a 15 kDa band (4) were the major products (top panel); NAGE showed unaltered RNA content and
CLP mobility (bottom). (D) SRPK1-phosphorylated HBc183 CLPs. Note the additional intermediate mobility bands
2 and 3 (top panel). Running the 16 h sample along a set of C terminally truncated HBc proteins (lower panel) allowed
to approximately map the cleavage sites, as outlined in the scheme at the bottom. (E) SRPK1-phosphorylated
HBc183_F97L CLPs. The cleavage pattern with bands 1, 2, 3, 4 and accumulation of band 3 (top panel) was as for
SRPK1-coexpressed HBc183; also in NAGE (bottom panels) the much weaker RNA signals as well as the equally
strong protein signals remained unaltered.
https://doi.org/10.1371/journal.ppat.1007488.g007
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Structural comparison of non-phosphorylated versus seven-fold
phosphorylated HBc183 CLPs by cryoEM
To directly assess the impact of seven-fold CTD phosphorylation and/or low RNA content on
capsid structure we analyzed nonphosphorylated vs. SRPK1-phosphorylated HBc183 CLPs by
cryoEM (S10A and S10 Fig) and calculated image reconstructions (Fig 8) at 7.8 Å (B = 707 Å2)
and 7.9 Å (B = 979 Å2) resolution (S10C Fig). Most striking was a distinct shell of internal den-
sity exclusively in the non-phosphorylated particles (Fig 8B) which must represent CTDs plus
packaged RNA. The relatively high B-factors suggested some structural heterogeneity within
each CLP class, hence the gross features in the shells of unmodified vs. phosphorylated parti-
cles appeared very similar. However, in defined areas significantly different grey value distri-
butions occurred (Fig 8C; see S2 Protocol for significance calculations). For the SRPK1
coexpressed CLPs they could be best described as reduced order in the N terminal regions
which flank the spikes (Fig 8C bottom vs. top: less red color around the three-fold axes), plus
an apparent stretching of the spike helices and the inter-dimer contact regions (Fig 8C bottom
vs. top: more blue color within the dimer contours).
To improve resolution for fitting these differences into atomic models of HBc we vitrified
additional aliquots of the same sample preparations which, fortuitously, had been stored for
1.5 years at 4˚C. Corroborating the high stability of HBc CLPs, NAGE, SDS-PAGE and Phos-
Fig 8. CryoEM comparison between non-phosphorylated and seven-fold CTD-phosphorylated HBc183 CLPs. (A) Surface representations from image
reconstructions at 7.8 Å and 7.9 Å resolution. The A, B, C, and D monomers of one asymmetric unit in the T = 4 HBc183 CLP are colored blue, cyan, red
and yellow. (B) Density representations of equatorial slices. Non-phosphorylated HBc183 CLPs display an unstructured shell of high density underneath
the inner surface (top) which was absent from the SRPK1 coexpressed particles (bottom) with their much lower RNA content. (C) Impact of seven-fold
phosphorylation and/or low RNA content on the structure of the assembly domain. The surface representations show close-ups of the two-fold symmetry
axes at 7.8 Å and 7.9 Å resolution, sharpened with B-factors of -797 Å2 and -979 Å2, respectively. For clarity densities at radii<127 Å and small disconnected
speckles were removed. Surface coloring reflects differences between the normalized unsharpened maps. Only differences with a confidence level of>99%
(Student´s t-test) are shown. Colored areas highlight extra densities in non-phosphorylated (red) and phospho-HBc CLPs (blue). The length of the scale bar
equals 2 nm. Numbers 2, 3 and 5 indicate the respectice symmetry axes. (D) Ordered internal protein density in seven-fold phosphorylated HBc183
CLPs. Shown are luminal close-ups of the five-fold symmetry axes; density accounted for by modelling the crystal structure of HBc149 CLPs (pdb: 1QGT)
into the reconstructions is color-coded as in (A); not accounted for density is shown in white. Note the tube-like structures extending all the way to the feet of
the spikes (one of the five highlighted as black continuous line) in the phospho-HBc CLPs. The extensions appear in direct contact with R112, part of the
inner CLP lining (S11B Fig).
https://doi.org/10.1371/journal.ppat.1007488.g008
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tag SDS-PAGE revealed no signs of degradation or loss of phosphorylation. Surprisingly, how-
ever, by 3D-classification the majority of these "aged" CLPs, especially the phosphorylated
ones, grouped into a distinct class from the bulk of fresh particles (vitrified within two weeks
post preparation) used above. The aged particle reconstructions had higher resolution and
lower B-factors (6.3 Å and 6.6 Å, and 555 Å2 and 466 Å2, respectively, for non-phosphorylated
vs. SRPK1-phosphorylated CLPs), in line with increased ordering with time. For the non-
phosphorylated CLPs the differences were only minor but for the phospho-HBc particles they
were pronounced. As in the comparison with fresh unmodified CLPs (Fig 8C) the freshly vitri-
fied phospho-CLPs showed extended spikes and less ordered N termini (S11A Fig, top)
whereas after ageing they appeared very similar to the non-phosphorylated ones (S11A Fig,
bottom). This suggests a conformational maturation process, although not necessarily in the
classic sense of gaining envelopment competence.
Fitting the HBc149-derived crystal structure 1QGT [16] into these reconstructions
accounted for most density in the assembly domains but left unaccounted internal density
close to the inner CLP surface, likely related to CTDs plus RNA in the non-phosphorylated
CLPs yet only CTDs in the phospho-CLPs. The undisturbed view onto the inner shell surface
of the latter particles revealed extensive tube-like structures around the 5-fold symmetry axes
(Fig 8D, bottom vs. top). Connecting to the last visible residues in the crystal structure they
probably represent residues from the linker plus the CTD. The respective density extended
towards the feet of the spikes, with apparently direct contacts to R112 in both fresh and
matured CLPs (S11B Fig). Their visibility implies rather stable interactions, perhaps including
electrostatic binding between R112 and phosphorylated CTD residues in the phospho-CLPs
(S9C and S9D Fig). Similar though less prominent extra density was also seen in the non-phos-
phorylated CLPs, although their high RNA content makes a clear distinction between nucleic
acid and protein residues difficult (S11B Fig).
The bulk of HBc183 in human hepatoma cells is similarly highly though
non-identically phosphorylated as SRPK1-coexpressed HBc183
Recent data suggest that most HBc in mammalian cells from replicating as well as non-repli-
cating vectors is phosphorylated [13, 52] yet the number of phospho-sites per HBc monomer
is unknown. We therefore analyzed HBc in intracellular capsids from the stable HBV produc-
ing TetOFF HepG2.117 line [84] by Phos-tag SDS-PAGE, using our recombinant phospho-
HBc183 proteins as markers. To minimize band distortions seen with crude cytoplasmic lysate
we first enriched capsids by sedimentation through 10–60% (w/v) Nycodenz gradients (Fig
9A; S12A Fig). The presence of HBV-typical replicative DNA intermediates was corroborated
by Southern blotting (Fig 9B); however, less vs. more mature species were barely separated and
the presence of empty particles [54] remains to be addressed.
Regardless of this, Phos-tag SDS-PAGE showed a comparably strong retardation of the
bulk HBc signals as for SRPK1-phosphorylated recombinant HBc183 (Fig 9C, short exposure).
Longer exposure revealed several very weak intermediate mobility bands in the HepG2.117
samples, similar to those seen for CLPs coexpressed with PKA and PKC, and for non-phos-
phorylated CLPs; however, >95% of the band intensity was concentrated in the slowest
migrating band. Though this would be in line with an SRPK1-like phosphorylation further
investigation using the phospho-CTD specific mAb T2212 [51] indicated a non-identical
phosphorylation pattern. As reported mAb T2212 did not recognize unmodified recombinant
HBc183, yet it reacted strongly with the PKA- and some of the PKC-phosphorylated HBc spe-
cies. Interestingly, fully SRPK1-phosphorylated HBc gave almost no signal whereas single ala-
nine replacements of the phospho acceptor sites S162, S168 and, weakly, S176 and S178 but
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not S170 restored reactivity (S12 Fig). Hence the T2212 epitope appears to depend on the pres-
ence of phosphoryl groups at some positions, including S170, yet their absence from nearby
sites.
Fig 9. The bulk of HBc183 in capsids from human hepatoma cells is highly phosphorylated. (A) Enrichment of
particulate HBc by Nycodenz gradient sedimentation. Cytoplasmic lysate from HBV producing HepG2.117 cells was
sedimented through a Nycodenz gradient. Fractions were analyzed by SDS-PAGE and CB staining (top panel; asterisks
mark a 21 kDa band possibly representing HBc183; the complete gel is shown in S12A Fig); by NAGE followed by
immunoblotting with the anti-HBc assembly domain mAb 312 as PO conjugate (middle panel); and by hybridization with a
32P-labeled HBV probe. (B) Southern blot for capsid-borne HBV DNA in individual gradient fractions. M, DNA marker
comprising HBV-specific fragments of the indicated sizes loaded in native ds form, or in heat-denatured ss form. (C) Phos-
Tag SDS-PAGE immunoblot. Aliquots from the respective gradient fractions and recombinant HBc183 coexpressed with
the indicated kinases, or not (ø), were separated by Phos-Tag SDS-PAGE and immuno-blotted with mAb 1D8. Short
exposure showed one band with comparably strong retardation as SRPK1-phosphorylated HBc183. Longer exposure (left
panel) revealed weak additional bands with mobilities similar to those of unmodified and PKC and PKA phosphorylated
HBc183 (arrowheads). (D) Enveloped capsids contain phosphorylated HBc183. PEG-precipitated particles in
supernatants from HepG2.117 cells, or from an HBc183 producing Huh7 line, H4-15 were analyzed by NAGE
immunoblotting alongside E. coli HBc183 CLPs. The blot was sequentially probed with mAb T2212 (anti-phospho-CTD),
mAb 312, and mAb 9H9 (anti-HBs). Note that T2212 detected only HBc from eukaryotic cells, including a low mobility
species that comigrated with HBsAg and was absent from the H4-15 samples; it therefore represents enveloped capsids.
Additional data employing mAb T2212 are presented in S12 Fig.
https://doi.org/10.1371/journal.ppat.1007488.g009
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To assess whether mAb T2212-reactive phospho-HBc species are present in enveloped par-
ticles we separated extracellular particles from HepG2.117 cells and from a new HBc183-only
expressing Huh7 line by NAGE; recombinant HBc183 CLPs served as control (Fig 9D). Immu-
noblotting revealed a fast migrating band in the human cell-derived samples which corre-
sponded to naked capsids, as indicated by comigration with bacterial HBc183 CLPs; as before,
the latter did not react with mAb T2212 but were detected by the anti-assembly domain mAb
312 (marked by ��). Importantly, mAb T2212 revealed a second, slower migrating band exclu-
sively in the HepG2.117 samples which also stained with the anti-HBs mAb 9H9 [85]. Hence
capsids containing phosphorylated HBc can be enveloped. More detailed conclusions will
require separation from the naked capsids and efficient fractionation of enveloped capsids
with differing nucleic acid content.
Discussion
Dynamic (de)phosphorylation events are long thought of as enabling hepadnaviral core pro-
teins to execute their multiple functions in the viral life-cycle but many details remained
obscure. The tools developed in this study, especially in combination, are beginning to shed
new light on these unresolved issues.
Our optimized E.coli coexpression system provides robust access to defined HBc species
phosphorylated by individual kinases, as shown here for SRPK1, PKA and PKC. Varying the
HBc part allows to pinpoint how specific mutations and/or the assembly status affect HBc´s
substrate quality for a given kinase; in addition, the recombinant phospho-HBc proteins will
make well-defined substrates to study phosphatases. Phos-tag SDS-PAGE was able to separate
HBc species containing from no to seven phosphoryl groups which together with MALDI-
TOF MS enabled us to map the seven SRPK1 target sites in the CTD. This, in turn, allowed
correlating the number of CTD phosphoryl groups with CLP RNA content, stability and CTD
exposure. Importantly, the new tools indicated that the bulk of HBc in human hepatoma cells
is similarly highly phosphorylated as the recombinant SRPK1 phosphorylated protein, albeit in
a non-identical pattern. Here we first discuss technical aspects of our study and then its impli-
cations for HBc phosphorylation in the viral life-cycle.
Relevance of recombinantly phosphorylated HBc
Our MS data confirmed the absence from E. coli BL21 cells of enzymes capable of phosphory-
lating any residue in HBc183 (Figs 3 and 4; S5 and S6 Figs). Hence all previously reported
properties of E. coli derived HBc CLPs relate to the fully unphosphorylated state. Vice versa,
co-expressing a eukaryotic kinase then allows to single out how that specific kinase acts on
HBc, as shown here for SRPK1 and per proof-of-principle for PKA and PKC.
There are still caveats for interpretation, including the concentration and ratio of kinase to
HBc substrate in the bacteria, plus the potential sequestration of CTD-embedded target sites in
the capsid interior. ATP is present in E. coli at concentrations of�1 mM [86] and thus not lim-
iting. However, a low translation rate of a kinase compared to HBc, or poor solubility and/or
low affinity for HBc could all affect phosphorylation efficiency. The higher levels of soluble
SRPK1ΔNS1 (S3 and S4 Figs) likely explain the homogeneous seven-fold phosphorylation
found here compared to the mixed phospho-HBc species seen upon coexpressing full-length
SRPK1 [11]. An impact of target sequestration on phosphorylation efficiency is supported by
the MS data for PKA coexpression which indicated predominantly three-fold phosphorylation
of self-assembling HBc183 (S7 Fig), yet four- and five-fold phosphorylation of the non-assem-
bling GFP-CTD protein (S6 Fig).
HBV core protein phosphorylation sites
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007488 December 19, 2018 16 / 31
For SRPK1 the seven identified phosphorylation sites likely represent the maximum num-
ber; notably they include T160 (Fig 5) although SRPK1 is mainly considered as a serine kinase
[72, 87]. Furthermore, the apparent stability of bacterial phospho-HBc in the absence of Phos-
Stop inhibitor suggests the absence of phosphatases able to revert the mammalian-type
phosphorylations.
A compromised substrate specificity in the E.coli system is unlikely because none of the
eleven S and twelve T residues upstream of the CTD showed any indication of phosphoryla-
tion when HBc140 or HBc149 were coexpressed with SRPK1 (S7 Fig).
In sum, these data advocate a broad applicability of our recombinant phospho-HBc system
to reveal the impact of individual kinases (and with adaptations, of phosphatases) on HBc.
Feasible distinction of different phospho-HBc species by Phos-tag
SDS-PAGE
Different from conventional SDS-PAGE Phos-tag SDS-PAGE resolved HBc species containing
from none to five or six phosphoryl groups. While higher phosphorylation generally correlated
with stronger retardation, discrimination amongst highly phosphorylated species was less
clear, also owing to sequence context specific effects. (Fig 5A and 5B). It will be interesting to
see whether variants with unusual Phos-tag mobility shifts also display specific biological fea-
tures. For instance, two of the three single-site mutations causing lower than average retarda-
tion, S162A and S170A (Fig 5C), had the strongest negative impact on pgRNA encapsidation
[47, 48, 88]. Coexpression with SRPK1 of additional HBc183 S/T>A mutants would provide a
unique, comprehensive panel of reference proteins for more systematic investigations.
Impact of sevenfold CTD phosphorylation on basic HBc particle
properties: RNA content, detergent stability and CTD exposure
Uniform seven-fold phosphorylation by SRPK1 enabled to correlate a defined phospho-status
with basic properties of HBc. Most striking was the drastic reduction in CLP RNA content
(Figs 2, 5, 6 and 7). This has not been seen with partly phosphorylated HBc or with phosphory-
lation mimicking S/T>D,E variants. For instance, a variant termed 7E with seven S/T>E
replacements in the CTD, expressed in HEK293 cells, reportedly contained still half as much
RNA as nonphosphorylated bacterial CLPs [89]; similar results were seen for an all-S>D vari-
ant (S7D) expressed in E.coli [13]. Likely, the much stronger impairment of RNA binding by
seven phosphoryl groups versus seven carboxyl groups is owed to their different chemistries.
Seryl- and threonyl-phosphomonoesters are dibasic acids. With pKa values of 1.2 and 6.5 [90]
even the second phosphoryl hydroxy group will be mostly deprotonated at physiological pH;
hence each phosphoryl group can contribute nearly two negative charges. Seven-fold CTD
phosphorylation would thus suffice to largely neutralize the 15 net positive charges (Fig 1),
minimize the CTD´s general RNA binding capacity, and explain the low RNA content of the
resulting CLPs.This interpretation is supported by inverse experiments in eukaryotic settings
where complete inhibition of CTD phosphorylation by S/T>A mutations led to the formation
of non-specifically RNA-filled rather than empty HBc CLPs [13, 89]. Practically, low RNA
CLPs from SRPK1 coexpression in E. coli of full-length HBc variants bearing heterologous
sequences could be of interest for vaccine applications [74].
Seven-fold phosphorylation and low RNA content had little impact on CLP stability against
SDS (Fig 6) whereas trypsin treatment revealed specific phosphorylation and/or RNA content-
dependent differences; their independence from the F97L mutation suggests that the structural
changes causing the premature virion secretion phenotype of the F97L variant are either very
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subtle or not sufficiently long-lived to be observed [91], as corroborated in a recent high reso-
lution cryoEM study [92].
Non-phosphorylated CLPs yielded one major HBc149-like product ("band 4" in Fig 7B and
7C), whereas the SRPK1-phosphorylated CLPs gave two additional, stable intermediates (Fig 7C
and 7D; S9 Fig). These data are reminiscent of but also distinct from artificially RNA-depleted
HBc-EEE vs. WT CLPs [37]; there, a band similar in size to our band 3 also accumulated over
time, however, in both wild-type and HBc-EEE CLPst. The more pronounced differences in our
experiments may relate to the higher number of modifications per CTD plus the chemical differ-
ences outlined above. Two models that could explain formation of distinct trypsin processing
products (S9C and S9D Fig) would invoke either complete extrusion of some CTDs, or the loop-
ing-out of selective trypsin target sites with the very C terminal CTD residues still internally dis-
posed. In the phospho-HBc CLPs this could be mediated by electrostatic interactions between the
phosphoryl groups and positively charged side-chains in the CTDs and/or on the inner CLP lin-
ing, as proposed for HBc-EEE CLPs [37]. Maintained integrity and RNA content of the trypsin-
treated CLPs (Fig 7B, 7C and 7E) appear in better accord with the looping-out model.
The current cryoEM reconstructions did not resolve this issue but they revealed distinct
phosphorylation-dependent differences. The lack in SRPK1-coexpressed HBc183 CLPs of
internal RNA density (Fig 8B) enabled allocating the remaining extra density to the linker plus
CTD residues which formed tube-like structures around the five-folds, in apparent contact
with residues lining the capsid lumen, i.e. R112 (S11B Fig). Freshly vitrified phospho-CLPs
showed well detectable local differences in their assembly domains compared to unmodified
CLPs which largely disappeared upon long-term storage. In particular the very N termini
adopted a more ordered conformation, as in both fresh and aged unmodified CLPs. A poten-
tial physiological relevance of this slow rearrangement in the phospho-CLPs remains to be
determined. Notably, though, replacement of the N-proximal P5 lowered virus secretion [93]
and P5 is close in space to residues 95-97 implied in interactions with L protein [94].
Implications of high-level HBc CTD phosphorylation for the HBV life-
cycle
The bulk of HBc183 in capsids from human cells was strongly retarded in Phos-tag SDS-PAGE
(Fig 9C, S12B Fig), in line with an independent report [13]. Comparison with the recombinant
phospho-HBc proteins indicated an SRPK1-like seven-fold phosphorylation status, in line
with a physiological role of SRPK1 as a HBc kinase [34, 43, 71]. However, Phos-tag retardation
alone would be also compatible with a slightly lower or higher phosphorylation extent (Fig 5).
Also, the strong reactivity of mAb T2212 with the human cell-derived but not the recombinant
phospho-HBc (S12 Fig) indicates at least one phosphorylation-dependent difference. If SRPK1
was indeed the main HBc kinase, (a) compatible phosphorylation pattern(s) could arise from
one or few selective dephosphorylation events. Alternatively, however, the combined action of
other kinases (and phosphatases) could lead to a similar pattern.
Notably, mAb T2212 detected phosphorylated HBc in enveloped particles (Fig 9), as pro-
posed for empty virions [52]. Further exploration using our new tools, with more efficient
separation of the various HBV particles [54], will help to accurately ascribe specific phosphory-
lation patterns to individual particle types.
At any rate does the high phosphorylation level of most HBc183 in human cells imply a
similar suppression of general RNA binding capacity as in recombinant SRPK1 phosphory-
lated HBc183. As outlined in Fig 10, in favor of viral replication this would counteract encapsi-
dation of irrelevant RNAs [13, 89] yet also impair pgRNA packaging, giving empty capsids
and empty virions. This dilemma could plausibly be resolved by partial dephosphorylation,
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possibly at just one site (Fig 5C). Most effective would be a phosphatase activity associated
with the pgRNA—P protein complex, providing spatio-temporal control of the dephosphory-
lation event(s); HBc dephosphorylation coincident with pgRNA packaging has indeed very
recently been suggested [95]. HBc dimers joining the nascent capsid, but not bulk HBc, could
then as well become partly dephosphorylated, enabling stable packaging of the entire 3.5 kb
pgRNA. With progressing dsDNA synthesis the co-packaged phosphatase activity could grad-
ually release more CTD phosphoryl groups until this electrostatic buffer is emptied [13, 26,
75]. One might further speculate that timely envelopment blocks the supply of dNTPs into the
capsid before the (+)-DNA gap is completely filled, and that this represents the most stable
state for a DNA containing nucleocapsid ready to leave the cell as virion. Conversely, after
infection of a new cell continued DNA synthesis plus re-phosphorylation might create an
excess of negative charge and destabilize the capsid in preparation for uncoating.
More work will be needed to substantiate this model, but the concept as such lets previous
statements on the importance of HBc phosphorylation for HBV replication appear
Fig 10. Implications of the high HBc phosphorylation—Low CLP RNA content correlation for specific pgRNA encapsidation in HBV infection. In
E.coli nonphosphorylated HBc183 CTDs have maximal positive charge and thus maximal electrostatic RNA binding capacity, generating RNA-filled
CLPs (Fig 1B). Seven-fold phosphorylation by SRPK1 neutralizes most positive charges, leading to virtually empty capsids. The similarly strong Phos-tag
retardation of most HBc183 from human cells indicates similarly high phosphorylation, whether by SRPK1 or a combination of kinases. Strongly
reduced RNA binding favors formation of empty capsids and then empty virions, perhaps the dominant pathway in vivo [52]. The backside of avoiding
irrelevant RNA packaging is a loss in specific pgRNA interaction capability. As blocking just one of the seven SRPK1 phosphorylation sites restored
substantial RNA packaging in bacteria we propose that the pgRNA/P protein complex, besides other host factors, also carries a protein phosphatase
(PPase) activity. This PPase would dephosphorylate only nearby HBc CTDs, and thus locally unleash their RNA binding potential in proximity to
pgRNA. This would go on with further HBc dimers until the shell is completed. Progressive dephosphorylation of the now internal CTDs by the PPase
activity could maintain electrostatic homeostasis, especially during the near doubling of negative charges associated with dsDNA formation. Targeted
nucleocapsid destabilization upon infection of a new cell could occur by CTD re-phosphorylation and completion of plus-strand DNA.
https://doi.org/10.1371/journal.ppat.1007488.g010
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oversimplified. Rather than directly promoting pgRNA encapsidation HBc phosphorylation
seems to act indirectly by blocking competing interactions with non-specific RNA. In turn,
with high-level HBc phosphorylation as default, dephoshorylation becomes as important for
viral replication as phosphorylation. Hence production of replication-competent HBV nucleo-
capsids appears to depend on an intricately balanced level of HBc phosphorylation. The excess
of empty over genome-containing HB virions [52, 60] indicates that proper execution of this
program is delicate; hence even small perturbations might have severe consequences, inviting
therapeutic exploitation, e.g. by kinase [96] or phosphatase inhibitors. However, such strate-
gies will require a deeper understanding of the involved host enzymes and the substrate prop-
erties of HBc for which our study provides valuable new tools. On the basic side, these tools
can feasibly be adapted to other viruses, including but not limited to relatives of HBV [97].
Preliminary data indicate, for instance, that the core protein of DHBV, a virus capable of repli-
cating in human cells [98], is also highly phosphorylated (at eight yet to be mapped sites) by
human SRPK1 in the recombinant coexpression system whereas the core protein of the fish
Cichlid nackedna virus (CNDV; [97]) is not. Compatibility with the cellular kinases and phos-
phatases may thus well be a determinant of viral host and tissue tropism.
Materials and methods
Plasmid constructs
HBc expression vector pET28a2-HBc183 [69] carries a T7 promoter controlled synthetic HBc
gene [68] for a genotype D (GenBank: V01460.1) core protein. The HBc183opt ORF used here
encodes the same aa sequence but was adapted to E. coli codon usage (GeneOptimizer software;
ThermoFisher/GeneArt), increasing CLP yields ~3-fold (S1 Fig). The new pRSF expression vec-
tors are based on pRSFDuet-1 (Novagen) which harbors two T7 promoter cassettes and the lacI
repressor gene for IPTG inducible coexpression of two ORFs. For HBc mono-expression the
HBc183opt ORF and its derivatives were usually inserted after the 5´ T7 promoter, with simulta-
neous deletion of the 3´ T7 promoter cassette (plasmids pRSF_T7-HBcNNNopt; NNN specifies
the last HBc aa present). For coexpression, the upstream T7 promoter was replaced by a Tet pro-
moter, and in addition a gene for the Tet repressor was inserted into the plasmid (S2A Fig) for
separate inducibility by anhydrotetracycline (AHT). Kinase ORFs were inserted under Tet pro-
moter control, HBc ORFs under T7 promoter control (plasmids pRSF_Tet-X_T7-HBcNNNopt,
where X denotes the ORF under Tet promoter control). Employed kinase ORFs encoded an N-
terminally His6-tagged version of SRPK1ΔNS1 [72]; the catalytic subunit alpha isoform 1 (aa
1–351) of PKA (NP_032880.1); and the C-terminal catalytic domain (aa 397–740) of human
PKC theta isoform X1 (XP_005252553.1). The latter two ORFs had previously been expressed in
bacteria [79, 80] and here were obtained as E. coli expression optimized DNA strings (Thermo-
Fisher/GeneArt). In the non-assembling CTD control constructs the HBc aa 1–145 part was
replaced by the ORF for N-terminally His6-tagged eGFP [99] followed by a Gly2 linker and a
recognition site for TEV protease (see Fig 4A). Cloning was done by conventional restriction-
based methods or using the Q5 mutagenesis kit (NEB). All constructs were verified by Sanger
sequencing.
Expression of recombinant proteins in E. coli and HBc CLP enrichment
Expression of HBc CLPs followed previously described procedures [99, 100], as detailed in ref-
erence [101]. In brief, E. coli BL21�CP served as expression host. T7 promoter and Tet pro-
moter driven expression from the pRSF plasmids were induced by IPTG (1 mM final
concentration) and/or 0.2 μg/ml AHT, respectively; cultures (usually 200 ml) were then shaken
for 12–16 h at 20–25˚C. Cell lysis included treatment with lysozyme, Triton X-100 and
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benzonase (Merck-Millipore) in the presence of protease-inhibitor cocktail (Roche) with sub-
sequent sonication; in kinase coexpressions, Phos-Stop phosphatase inhibitor (Roche) was
included. Cleared cell lysates were subjected to sedimentation (TST41.14 rotor; 41,000 rpm for
2 h at 20˚C) through 10%-60% sucrose step gradients in TN150 buffer (25 mM Tris/HCl, 150
mM NaCl, pH 7.4). For longer term storage at -80˚C, peak fractions were dialysed into storage
buffer (50 mM Tris/HCl pH 7.5, 5 mM EDTA, 5% (w/v) sucrose, 2 mM DTT). Isolated CTD
peptides from TEV-cleavable GFP fusions were obtained as detailed in S1 Protocol.
Native agarose gel electrophoresis (NAGE)
NAGE was performed in 1% agarose gels in 1x TAE buffer (40 mM Tris, 20 mM acetic acid, 1
mM EDTA) as previously described [9, 23, 99]. For routine detection of nucleic acids gels con-
tained 0.5 μg/ml ethidium bromide (EB); subsequent protein staining was done using Coo-
massie Brilliant Blue R250 (CB) followed by extensive destaining in fixing buffer (50% MeOH,
7% acetic acid, v/v in H2O).
Alternatively, gels run without EB were stained for RNA using 1x Sybr Green 2 (SG2) RNA
stain in TAE buffer (from 10,000x in DMSO; FMC Bioproducts), followed by protein staining
with ready-to-use Sypro Ruby (SR) Protein Gel Stain (BioRad). Fluorescence signals were
recorded using a laser Scanner (Typhoon FLA 7000; GE Healthcare) set at excitation 473 nm /
filter Y520 nm (SG2) and 473 nm / filter O580 nm (SR). Signals were quantified using Image-
Quant software. Higher quantitation accuracy was achieved by several adapations of the proto-
col, as described next.
HBc CLP RNA content by fluorescence intensity of RNA versus protein
staining after NAGE—Improved protocol
Critical issues for robust signal quantitation included weak SG2 staining (especially for low
RNA content CLPs), concentration-dependent variations in SR signal intensities, SG2 to SR
signal carry-over during Laser scanning, and high background staining. Implemented coun-
termeasures were to use gels no thicker than 5–6 mm; loading similar protein amounts of dif-
ferent CLPs and possibly two different amounts of the same CLPs; and including on each gel a
well-characterized wild-type CLP preparation as standard to account for variations in staining
intensity. SG2 staining over background was improved by doubling the dye concentration
(1:5,000 dilution), a 1 h staining period, plus�3 washes with TAE buffer prior to SG2 laser
scanning. For improved SR staining gels were washed twice in fixing buffer, after which the
SG2 staining was no longer detectable; fixation also prevented band broadening by diffusion
during the subsequent overnight incubation in SR protein gel stain. After two additional
washes in distilled water SR fluorescence was recorded as described above. For each gel, the
ratio of SG2: SR fluorescence intensity in the wild-type HBc183 standard was set to 100% to
which the respective intensity ratios from the test CLPs were normalized. Applying this proce-
dure reduced the calculated relative RNA content of CTD-less and SRPK1-phosphorylated
CLPs from >25% of that of unmodified HBc183 CLPs (Fig 2C) to�10% (Fig 5C, S8 Fig).
HBc CLP RNA content by UV/VIS spectrometry
RNA content was calculated from CLP sample absorbances at 260, 280, 340 and 360 nm [73].
For high purity CLP preparations, e.g. HBc183 CLPs from two sequential sucrose gradients
[101], ten-fold dilutions in H2O were measured in 1 cm path length cuvettes in an Ultrospec
7000 instrument (GE Healthcare). For single gradient CLP preparations which may contain
free RNA [101] aliquots from the respective fractions (routinely containing 0.5–4 mg/ml of
HBc protein) were incubated with 1/100 (w/w) of RNase A for 30 min at room temperature,
HBV core protein phosphorylation sites
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007488 December 19, 2018 21 / 31
then dialyzed (30 kDa MWCO) against TN 150 buffer. UV/VIS absorbances of the resulting
solutions were then monitored without further dilution in a QIAxpert instrument operating
with 0.1 cm path length (2 μl volume) microcuvettes. Molar nucleotide per core protein mono-
mer (N/P) ratios were calculated as described [73].
Phos-tag SDS-PAGE
Mn2+-Phos-tag SDS-PAGE was performed by adding Phos-tag acrylamide AAL-107 (Wako
Pure Chemical Corporation) plus MnCl2 to the acrylamide solutions for conventional La¨mmli
SDS-PAGE resolving gels, as recommended by the manufacturer. In our hands, the best sepa-
ration of differently phosphorylated HBc183 species was obtained using 15% acrylamide gels
supplemented with 75 μM Phos-tag acrylamide and 150 μM MnCl2.
Immunoblotting
Immunoblotting after NAGE or conventional SDS-PAGE was performed as previously
described [69, 102]. Low transfer efficiency to polyvinylidene difluoride (PVDF) membrane
after Phos-tag SDS-PAGE gels was improved by sequentially soaking the gels for 10 min each
in transfer buffer A (39 mM glycine, 48 mM Tris, 3.75% (w/v) SDS, 20% (v/v) MeOH) contain-
ing 10 mM EDTA, 1 mM EDTA, and no EDTA, plus the use of a wet blot rather than a semi-
dry transfer system. HBc specific antibodies employed were the anti-assembly domain mouse
mAbs 312 [103] and 1D8 [82], both recognizing a linear epitope exposed on intact CLPs and
SDS-denatured HBc protein; the capsid-specific mAbs 275 [104] and 3120 [105], obtained
from Tokyo Future Style, Inc. (catalogue no.: 2AHC22); and the anti-phospho-CTD mAb
T2212 [51], also from Tokyo Future Style (catalogue no.: 2AHC23). HBsAg on NAGE blots
was detected by human mAb 9H9 [85] which recognizes a conformational epitope in S. Bound
mAbs were visualized using horse raddish peroxidase (PO), either as direct mAb conjugate or
via appropriate secondary antibody-PO conjugates, and chemiluminescent substrates.
HBc CLP sensitivity against SDS
About 5 μg of sucrose gradient enriched HBc CLPs were incubated for 30 min with increasing
amounts of a 6x DNA loading buffer containing 0.48% SDS (NEB Purple) to yield final SDS
concentrations from 0.024% to 0.24%; samples incubated in a non-denaturing 6x loading
buffer served as control. Reaction products were monitored by NAGE in 1% gels; EB fluores-
cence signals were recorded using a laser scanner (excitation 532 nm / filter O580 nm). Pro-
teins were subsequently stained by CB.
HBc CLP sensitivity against trypsin
For partial trypsin digests the respective HBc CLPs were incubated with 1/100 (w/w) the
amount of sequencing grade trypsin (Promega) in TN50 buffer (25 mM Tris/HCl, 50 mM
NaCl, pH 7.5) at 30˚C. At various time points aliquots were withdrawn and digestion was
stopped by adding 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF; Appli-
chem) to a final concentration of 0.2 mM. Formation of cleavage products and intactness of
particles were analyzed by SDS-PAGE and NAGE.
Mass spectrometry (MS)
MS analyses were performed at the Institut de Biologie et Chimie des Prote´ines, UMR5086,
CNRS/Universite´ Lyon 1, France on a Sciex Voyager DE-PRO MALDI-TOF instrument,
using sucrose gradient enriched CLPs diluted 1:100 (v/v) in sinapic acid as matrix.
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Electron microscopy and image processing
Electron microscopy was carried out in the Edinburgh, UK, cryoEM facility. Detailed proce-
dures for sample preparation, micrograph recording, particle selection, image processing,
refinement, difference map calculation, and molecular fitting are given in S2 Protocol. In brief,
gradient-enriched CLP samples were vitrifed as described [106] using a manual freezing appa-
ratus with an environmental chamber [107] at room temperature. Before use, grids (Quantifoil
R1.3/1.2) were glow discharged in air for 1 min with a current of 30 μA using a Quorumtec
sputter coater. Micrographs were recorded on a FEI Tecnai F20 microscope operated at 200
kV and a 8192 pixels x 8192 pixels CMOS camera (TVIPS F816). Only particles with round
shape and crisp appearance were subsequently used for reconstructions. Resolution and B-fac-
tors were calculated with Relion [108]. Fitting was done using Chimera [109], based on pdb
1QGT [16].
Human cells and culture conditions
The human hepatoma cell line HepG2 and its TetOFF HBV derivative HepG2.117 [84] were
cultured as described [84, 110]. The stable, constitutively HBc183 producing cell line H4-15
was derived from the human hepatoma cell line Huh7 by CRISPR/Cas9-mediated homologous
recombination of a HBc expression cassette into the AAVS1 locus (Peter Zimmermann, MSc
thesis; University of Freiburg, 2017).
Enrichment of HBV particles from human hepatoma cells
Cytoplasmic HBV capsids were obtained from TetOFF HepG2.117 cells cultured for 10 days
in the absence of doxycycline [84]. Cytoplasmic lysates were prepared using NP40 lysis buffer
(50 mM Tris/HCl, 140 mM NaCl, pH 8, with 0.5% (v/v) NP40 detergent) supplemented with
Phos-Stop. To enrich capsids, lysates were sedimented through a 10% - 60% (w/v) Nycodenz
step gradient for 2 h at 4˚C in a TST 41.14 rotor at 41,000 rpm (302,500 g) and harvested in 14
fractions. Detection of HBV DNA in capsids and by Southern blotting was performed using
32P labeled HBV DNA probes as described [84, 111]. Extracellular particles in the culture
supernatants of HepG2.117 and H4-15 cells were enriched by precipitation with PEG8000 [84,
112].
Statistical analyses
Unless indicated otherwise data are expressed as mean ± standard deviation (SD) from�3
experiments. Comparisons between multiple groups were performed using One-way ANOVA
and Tukey´s post test (Graphpad Prism 5). Differences between means of two paired groups
were evaluated using Student’s t-test. P-values of p<0.05 were regarded as statistically
significant.
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